Clorox Q1 net sales rise 27% to $1.76 billion; company raises EPS and gross margin outlook
Clorox reported first-quarter fiscal 2025 results for the period ended September 30, 2024, with net sales up 27% to $1.76 billion and diluted EPS of $0.80, compared with $0.17 a year earlier. The company raised its fiscal 2025 gross margin and adjusted EPS outlook while keeping its net sales outlook of flat to down 2%, and the results include a one-time after-tax charge of $118 million from the sale of its Better Health VMS business.
Key points
- Net sales rose 27% to $1.76 billion, driven largely by higher volume as the company lapped the August 2023 cyberattack; organic sales rose 31%.
- Diluted EPS was $0.80 versus $0.17 a year earlier, including a 94 cent charge from the Better Health VMS sale; adjusted EPS was $1.86 versus $0.49.
- Fiscal 2025 adjusted EPS outlook was raised to $6.65 to $6.90 from $6.55 to $6.80, and gross margin is now expected to rise about 100 to 150 basis points.
- Year-to-date net cash provided by operations was $221 million, compared with $20 million a year earlier.
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:12 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 30, 2024.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.